key: cord-0947867-3gh0n793
authors: Fernández-de-las-Peñas, César; Torres-Macho, Juan; Velasco-Arribas, Maria; Arias-Navalón, Jose A.; Guijarro, Carlos; Hernández-Barrera, Valentín; Canto-Diez, Mª Gabriela
title: Similar Prevalence of Long-Term Post-COVID Symptoms in Patients with Asthma: A Case-Control Study
date: 2021-05-03
journal: J Infect
DOI: 10.1016/j.jinf.2021.04.034
sha: 99f52e2777576b6cb1fde8fea228419545a23d7e
doc_id: 947867
cord_uid: 3gh0n793

nan

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disproportionately impacts people with some pre-existing medical comorbidities, e.g., diabetes, hypertension or cardiovascular conditions. For instance, hypertensive patients exhibit higher mortality risk than normotensive patients with SARS-CoV-2 infection. 1 Asthma is another medical comorbidity which could influence the course of COVID-19.

Interestingly, asthma seems to be a "protective factor", since the risk of presenting severe COVID-19 in people with asthma is small; 2 although a recent meta-analysis concluded that pre-existing asthma was a predictor of intubation particularly just in young and obese COVID-19 patients. 3 Current evidence supports the presence of long-COVID, that is, individuals who have recovered from COVID-19 but exhibit symptoms after the acute phase far longer than it would be expected. 4 In a letter to the editor in Journal of Infection, Garrigues Participants provided informed consent before collecting data.

Clinical and hospitalization data were collected from hospital records.

Participants were scheduled for a telephonic interview by trained healthcare professionals around 7.5 months (SD 0.5) after hospital discharge. Patients were asked to report the presence of symptoms after hospitalization, and if these symptoms persisted at the time of the study. Participants were systematically asked about a predefined list of post-COVID symptoms including fatigue, dyspnea at rest, dyspnoea on exertion, chest pain, headache, anosmia, ageusia, cough, palpitations, diarrhea, cognitive blunting/brain fog, or memory loss, but they were free to report any further symptom that they considered relevant.

Quality Index (PSQI) were used to assess anxiety/depression symptoms and sleep quality, respectively, as both can be adequately administered by telephone. 8 We considered cut-off scores considered on the Spanish population for determining the presence of anxiety (HADS-A≥12/21 points) and depressive (HADS-D≥10/21 points) symptoms and poor sleep quality (PSQI≥8/21 points).

The statistical analysis was conducted with STATA 16. Table) .

Higher number of patients with asthma also presented diabetes as comorbid condition when compared with those without asthma (P=0.045). (Table) .

Identification of the phenotype of patients at a higher risk of death during the acute infection or a higher risk of developing post-COVID symptoms is crucial. In our sample, the presence of long-term post-COVID symptoms was similar between patients with and without pre-existing asthma, suggesting that asthma seems not to be a risk factor for more severe long-term post-COVID symptoms but either was a "protective" factor for that. Our results are contrary to those found by Garcia-Pachon et al in their

letter to the Editor. 7 It should be considered that Garcia-Pachon et al did not include a "control" group without asthma and also included a shorter follow-up. 7 Additionally, these authors included non-hospitalized patients, which could explain the discrepancies.

Fatigue and dyspnea where the most common post-COVID symptoms in agreement with current literature, 5,6 but the presence of dyspnoea with exertion was more frequent in patients suffering from asthma. Distinction between dyspnoea at rest and on exertion maybe crucial in these patients.

Our study has limitations. First, the prevalence of asthma in our sample was 7.6%, in agreement with a meta-analysis reporting a pooled prevalence of asthma in COVID-19 patients of 7.46% (95%CI 6.25-8.67); 10 however, this sample could be considered small. Second, we conducted the follow-up by telephone. Third, just hospitalized patients were included. Fourth, we did not collect objective measures of COVID-19 disease such as inflammatory biomarkers. Finally, we collected data crosssectionally; therefore, future longitudinal studies are needed. 

Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study

Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients J Asthma

How to define it and how to manage it

Postdischarge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study

A: Anxiety; D: Depression)

PSQI: Pittsburgh Sleep Quality Index; SD: Standard Deviation * Significant differences between asthmatic and non-asthmatic patients

The authors declare no conflict of interest Funding None